Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1–d2–d3) in patients with refractory solid tumors-Reference-Cited by-同舟云学术

Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1–d2–d3) in patients with refractory solid tumors

Published:2006-10-10 Issue:5 Volume:59 Page:689-695
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Campone M.,Isambert N.,Bourbouloux E.,Maury S.,Monin-Baroille P.,Berille J.,Fumoleau P.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-006-0349-8.pdf

Reference8 articles.

1. Legha SS, Grose WE, Bodey GP (1978) Phase I study of Hycanthone. Cancer Treat Rep 62(8):1173–1176

2. Kovach JS, Moertel CG, Schutt AJ, Eagan RT (1979) Phase I study of Hycanthone. Cancer Treat Rep 63(11-12):1965–1969

3. Schutt AJ, Dalton RJ, Kovach JS et al (1983) Phase II study of Hycanthone in patients with advanced colorectal carcinoma. Cancer Treat Rep 67(6):593–594

4. LoRusso PM, Foster BJ, Wozniak A, Heilbrun LK et al (2000) Phase I pharmacokinetic study of the novel antitumor agent SR233377. Clin Cancer Res 6:3088–3094

5. Stevenson JP, DeMaria D, Reilly D et al (1999) Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule. Cancer Chemother Pharmacol 44:228–234

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and evaluation of new 3-substituted-4-chloro-thioxanthone derivatives as potent anti-breast cancer agents;Arabian Journal of Chemistry;2019-12

2. A Century of Thioxanthones: Through Synthesis and Biological Applications;Current Medicinal Chemistry;2013-04-01

3. Nanocarriers for the targeted treatment of ovarian cancers;Biomaterials;2013-01

4. Dual inhibitors of P-glycoprotein and tumor cell growth: (Re)discovering thioxanthones;Biochemical Pharmacology;2012-01

5. A Phase I Dose-Escalation Study of SR271425, an Intravenously Dosed Thioxanthone Analog, Administered Weekly in Patients With Refractory Solid Tumors;American Journal of Clinical Oncology;2009-02